Pfizer Responds To FDA Over Geodon Clinical Trial
On the heels of the U.S. Food and Drug Administration's warning over Pfizer Inc.'s repeated failure to properly monitor a trial of the bipolar disorder and schizophrenia drug Geodon, the drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article